Palisade Bio Announces Director and Officer Changes
Ticker: PALI · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: PALI
TL;DR
Palisade Bio (PALI) filing shows board and exec comp changes. Keep an eye on this.
AI Summary
On October 21, 2025, Palisade Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated, though specific details on new appointments or compensation changes are not yet elaborated in this initial report.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or new directions, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial performance.
Key Players & Entities
- PALISADE BIO, INC. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Carlsbad, California (location) — Address of Principal Executive Offices
- Seneca Biopharma, Inc. (company) — Former Company Name
- Neuralstem, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the election of directors, but does not specify the names of newly elected or departing directors in the provided text.
What are the details of the new compensatory arrangements for certain officers?
The filing states that there are new compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 21, 2025.
What is the principal executive office address for Palisade Bio, Inc.?
The principal executive office address for Palisade Bio, Inc. is 1902 Wright Place, Suite 200, Carlsbad, California, 92008.
Has Palisade Bio, Inc. operated under any previous names?
Yes, Palisade Bio, Inc. previously operated under the names Seneca Biopharma, Inc. and Neuralstem, Inc.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-10-22 16:35:20
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-018922.txt ( ) — 198KB
- pali-20251021.xsd (EX-101.SCH) — 3KB
- pali-20251021_lab.xml (EX-101.LAB) — 33KB
- pali-20251021_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2025 Palisade Bio, Inc. /s/ J.D. Finley By: J.D. Finley Chief Executive Officer